SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Celgene-CELG
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
804 71 0 CELG
Emcee:  rkrw Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
304 The CNBC reporter was Ted David. Sorry, don't know how it became Ted Allemargie-5/5/1999
303 Good interview on CNBC. Here's part of it. Celgene's first quarter earmargie-5/4/1999
302 CC tomorrow at 9 am and CEO Jackson on CNBC's Market Watch. videonewswireAbuckatatime-5/3/1999
301 There's some discussion of Thalidomide over on Rick's BVF thread for anBiomaven-4/30/1999
300 Someone (Schering and Chiro) see value in PDE IV inhibitor: biz.yahoo.com andMiljenko Zuanic-4/29/1999
299 If promotion of DNA oxidation (oxidative stress, as proposed in this article) iMiljenko Zuanic-4/27/1999
298 Peter, They (First Union from NY)are on the way to lose shirts, pants, and undMiljenko Zuanic-4/26/1999
297 I was amused to come across this article in Forbes by one Stephan Herrera from Biomaven-4/26/1999
296 Now they claim discovery of *hot water*, when thousands know that T *explainedMiljenko Zuanic-4/21/1999
295 FWIW....Believe CELG will receive favorable coverage in NEJM within next 45 dabigg e-4/10/1999
294 Rick, Missed T in Cochexia: Thalidomide (T) in the Symptomatic Treatment of CMiljenko Zuanic-4/8/1999
293 Bone Marrow Angiogenesis Has Prognostic Value in Multiple Myeloma: An Escaram(o)uche-4/8/1999
292 A Phase II Evaluation of Thalidomide in Patients with Metastatic Breastscaram(o)uche-4/8/1999
291 [PROC. AMER. ASSOC. CANCER RES. 40, March 1999] Copyright © 1999 by tscaram(o)uche-3/26/1999
290 <<Lotsa irons in fire......>> Yes, I guess so. T is going side byMiljenko Zuanic-3/22/1999
289 Lotsa irons in fire...... biz.yahoo.com Celgene and National Cancer Institutescaram(o)uche-3/22/1999
288 CELG news: biz.yahoo.com This is ongoing trial at NCI, not been sponsored by EMiljenko Zuanic-2/24/1999
287 Rick, Peter and others: First few words on racemic methylphenidate (racemic RiMiljenko Zuanic-2/16/1999
286 Rick, I assume that what they mean is that, for a given dose, the side effectsBiomaven-2/16/1999
285 <i>its side effect profile was comparable to its racemate</i> Miljscaram(o)uche-2/16/1999
284 CELG announces launch of Canadian clinical trial...IND for to begin studies forLLCF-2/16/1999
283 Today LA times (business section) has short article on Abgenix (ABGX). Issue isMiljenko Zuanic-2/15/1999
282 CELG reiterated "strong buy" at Prudential. DAK LLCF-2/12/1999
281 WSJ and NY Times have extensive articles on ENMD this morning. Both have a notHenry Niman-2/12/1999
280 Miljenko: <<PS: So, are you now back to ENMD?>> Not yet. I like John Bloxom-2/11/1999
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News